McKinley, Spanberger Introduce Bipartisan Legislation
The following press release was posted on Rep. David B. McKinley’s (R-WV-1) website on May 19, 2021. The press release can be accessed by clicking HERE. WASHINGTON – Today, Reps. David…
Ryan White Clinics Endorse McKinley-Spanberger Legislation to Prohibit Discrimination Against 340B Safety Net Providers, Protect Program Integrity
PRESS STATEMENT: FOR IMMEDIATE RELEASE Contact: Peggy.Tighe@PowersLaw.com July 9, 2021: RWC-340B, a national association of Ryan White HIV clinics, enthusiastically supports introduction of the PROTECT Act by Representatives McKinley (R-WV)…
Supreme Court to Review Three Cases With Implications for 340B Covered Entities
The Supreme Court has agreed to review three cases in its next term that have potential impact on 340B covered entities. First, the Supreme Court will review AHA, et al.…
Boehringer Ingelheim Latest Manufacturer to Announce It Will No Longer Offer 340B Discounts at Most Contract Pharmacies
By letter dated June 30, 2021, drug manufacturer Boehringer Ingelheim Pharmaceuticals, Inc. notified covered entities that it will no longer honor all 340B contract pharmacy arrangements, effective August 1, 2021. …
Secretary of HHS Names ADR Board Members
As expected, on June 21, the Secretary of HHS appointed Alternative Dispute Resolution (ADR) Board members. ADR Board members are government representatives (not private stakeholders) from three government agencies: HHS…
HHS Appoints 340B ADR Board Members
The Powers team was informed today that the Secretary of HHS has signed a memorandum appointing members to the 340B Alternative Dispute Resolution Board (ADR Board). Appointment of ADR Board…
Filings in Drug Manufacturer Lawsuits Following HHS’s May 17 Letter
Following a favorable May 17 Letter (the “Letter”) issued by HHS requiring six drug companies to restart 340B pricing on drugs shipped to contract pharmacies or risk civil monetary penalties,…
HRSA Informs Six Manufacturers That Their Contract Pharmacy Policies Violate the 340B Statute
Yesterday, HRSA Acting Administrator Diana Espinosa sent letters to Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics making clear to the manufacturers that their restrictions on access to…
Gilead’s HIV Drug Reimbursement Cut Will be Devastating, 340B Covered Entities Say
Drug manufacturer Gilead recently announced that a huge cut in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free through Gilead’s Advancing Access patient…
NY State 340B Providers Get More Time to Challenge Reimbursement Change
On April 6th, 2021, the New York legislature announced that it was delaying a controversial policy that would require the New York Medicaid program to carve out the pharmacy benefit…